Marc‐Oliver Grimm
Impact in
- Pulmonary and Respiratory Medicine top 0.2%
- Renal cell carcinoma treatment
- Prostate Cancer Diagnosis and Treatment
- Oncology top 0.5%
- Cancer Immunotherapy and Biomarkers
Papers in
-
- Renal cell carcinoma treatment 67
- Prostate Cancer Treatment and Research 29
- Prostate Cancer Diagnosis and Treatment 17
- Surgery 83
- Bladder and Urothelial Cancer Treatments 70
- Urinary and Genital Oncology Studies 15
- Co-authors
- Elizabeth R. Plimack (5 shared papers)Jens Bedke (12 shared papers)Margitta M. Retz (6 shared papers)José Ángel Arranz (2 shared papers)Andrea Necchi (4 shared papers)Sumanta Kumar Pal (2 shared papers)Arlene Odelia Siefker-Radtke (3 shared papers)Padmanee Sharma (3 shared papers)
- Journals
- Annals of Oncology (20 papers)European Urology (16 papers)The Journal of Urology (9 papers)The Lancet Oncology (8 papers)Cancers (5 papers)
- Partner nations
- GermanyUnited StatesFrance
In The Last Decade
Marc‐Oliver Grimm
227 papers receiving 13.6k citations
Marc‐Oliver Grimm's Hit Papers
Peers
Comparison fields: 5 of 140
- Pulmonary and Respiratory Medicine 5.6k
- Oncology 4.7k
- Urology 794
- Cancer Research 1.4k
- Surgery 3.7k
Countries citing papers authored by Marc‐Oliver Grimm
This map shows the geographic impact of Marc‐Oliver Grimm's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marc‐Oliver Grimm with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marc‐Oliver Grimm more than expected).
Fields of papers citing papers by Marc‐Oliver Grimm
This network shows the impact of papers produced by Marc‐Oliver Grimm. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marc‐Oliver Grimm. The network helps show where Marc‐Oliver Grimm may publish in the future.
Co-authors
The 25 scholars most cited alongside Marc‐Oliver Grimm, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 244 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma Hit paper breakdown → | 2018 | 3643 |
| 2 | Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial Hit paper breakdown → | 2017 | 1377 |
| 3 | Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial Hit paper breakdown → | 2019 | 643 |
| 4 | Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial Hit paper breakdown → | 2020 | 410 |
| 5 | Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial Hit paper breakdown → | 2020 | 400 |
| 6 | Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma Hit paper breakdown → | 2020 | 351 |
| 7 | 1999 | 310 | |
| 8 | 2011 | 267 | |
| 9 | 2017 | 260 | |
| 10 | An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer Hit paper breakdown → | 2021 | 244 |
| 11 | 2005 | 240 | |
| 12 | 2003 | 230 | |
| 13 | 2019 | 211 | |
| 14 | Conditional survival and long‐term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma Hit paper breakdown → | 2022 | 210 |
| 15 | Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial Hit paper breakdown → | 2022 | 210 |
| 16 | 2015 | 196 | |
| 17 | 2020 | 189 | |
| 18 | 2009 | 186 | |
| 19 | 2013 | 184 | |
| 20 | 2016 | 146 |
About Marc‐Oliver Grimm
Marc‐Oliver Grimm is a scholar working on Pulmonary and Respiratory Medicine, Surgery, Oncology, Urology and Cancer Research, having authored 244 papers that have together received 13.8k indexed citations. Recurring topics across this work include Bladder and Urothelial Cancer Treatments (70 papers), Renal cell carcinoma treatment (67 papers), Cancer Immunotherapy and Biomarkers (35 papers), Prostate Cancer Treatment and Research (29 papers), Renal and related cancers (17 papers), Prostate Cancer Diagnosis and Treatment (17 papers), Urinary and Genital Oncology Studies (15 papers) and Cancer Genomics and Diagnostics (14 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (5.6k citations), Oncology (4.7k citations), Urology (794 citations), Cancer Research (1.4k citations) and Surgery (3.7k citations). Marc‐Oliver Grimm has collaborated with scholars based in Germany, United States and France. Frequent co-authors include Elizabeth R. Plimack, Jens Bedke, Margitta M. Retz, José Ángel Arranz, Andrea Necchi, Sumanta Kumar Pal, Arlene Odelia Siefker-Radtke, Padmanee Sharma, Matthew D. Galsky and Chikara Οhyama. Their work appears in journals such as Annals of Oncology, European Urology, The Journal of Urology, The Lancet Oncology and Cancers.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.